1. Nurix announces participation in multiple investor conferences throughout September. 2. CEO and executive team will lead discussions on targeted protein degradation. 3. Key topics include drug development in cancer and inflammatory diseases. 4. Webcasts of the events will be made available for investors. 5. Focus remains on innovative drug design and collaborations with major partners.
Executive participation in conferences indicates strong investor engagement, potentially driving interest and investments. Historical instances of positive responses follow investor events for biotech firms.
The announcement reflects active efforts to engage with the investor community, highlighting the potential for increased market interest and confidence in NRIX's innovative pipeline.
The immediate attention from investor conferences can drive short-term price movements, as investors react quickly to new insights provided during presentations.
SAN FRANCISCO, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that Arthur T. Sands, M.D., Ph.D., president and chief executive officer, Hans van Houte, chief financial officer, John Northcott, chief commercial officer, and Jason Kantor, Ph.D., chief business officer, will participate in several investor conferences in September.
The fireside chats and corporate presentations will be webcast live and may be accessed via a link in the Investors section of the Nurix website. The archived webcasts will be available for 30 days after the events.
About Nurix Therapeutics, Inc.
Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases. Nurix's wholly owned, clinical stage pipeline includes degraders of Bruton's tyrosine kinase (BTK), a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. Nurix also is advancing multiple potentially first-in-class or best-in-class degraders and degrader antibody conjugates (DACs) in its preclinical pipeline. Nurix's partnered drug discovery pipeline consists of a preclinical stage degrader of STAT6, a clinical stage degrader of IRAK4 in collaboration with Gilead, as well as multiple additional programs under collaboration agreements with Gilead Sciences, Inc., Sanofi S.A. and Pfizer Inc., within which Nurix retains certain options for co-development, co-commercialization and profit sharing in the United States for multiple drug candidates. Powered by a fully AI-integrated discovery engine capable of tackling any protein class, and coupled with unparalleled ligase expertise, Nurix's dedicated team has built a formidable advantage in translating the science of targeted protein degradation into clinical advancements. Nurix aims to establish degrader-based treatments at the forefront of patient care, writing medicine's next chapter with a new script to outmatch disease. Nurix is headquartered in San Francisco, California. For additional information visit http://www.nurixtx.com.
Contacts:
Investors
Kris Fortner
Nurix Therapeutics, Inc.
ir@nurixtx.com
Elizabeth Wolffe, Ph.D.
Wheelhouse Life Science Advisors
lwolffe@wheelhouselsa.com
Media
Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com
